Humanwell Healthcare (600079.SH): HW201877 capsules enter Phase II clinical trial study

Humanwell Healthcare (600079.SH) announced that its wholly-owned subsidiary Hubei Biomedical Industry Technology Research Institute Co., Ltd. (hereinafter referred to as "Research Institute Co., Ltd.") recently posted the Phase IIa clinical trial registration information for HW201877 capsules on the National Medical Products Administration's Drug Clinical Trial Registration and Information Disclosure Platform. HW201877 capsules obtained the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration in March 2025 (the clinical trial applicant was originally the company's wholly-owned subsidiary Wuhan Humanwell Innovative Drug Research and Development Center Co., Ltd., and was transferred to Research Institute Co., Ltd. in September 2026). The approved clinical indication is inflammatory bowel disease. Inflammatory bowel disease (IBD) is a chronic, non-specific, relapsing, inflammatory disease that mainly affects the gastrointestinal tract, primarily including ulcerative colitis (UC) and Crohn's disease (CD). According to Insight database statistics, there are currently no drugs with the same target and same indication approved for marketing in China. As of now, the cumulative R&D investment in this project is approximately RMB60 million.